US 7,563,760 B2
P-selectin ligand protein
Glenn R. Larsen, Sudbury, Mass. (US); Dianne S. Sako, Boston, Mass. (US); Xiao-Jia Chang, Newton Centre, Mass. (US); Geertruida M. Veldman, Sudbury, Mass. (US); Dale Cumming, Acton, Mass. (US); Ravindra Kumar, Belmont, Mass. (US); and Gray Shaw, Cambridge, Mass. (US)
Assigned to Genetics Institute, LLC, Cambridge, Mass. (US)
Filed on Aug. 21, 2001, as Appl. No. 9/935,144.
Application 09/935144 is a continuation of application No. 08/713556, filed on Aug. 30, 1996, granted, now 6,277,975.
Application 08/713556 is a continuation in part of application No. 08/428734, filed on Apr. 25, 1995, granted, now 5,843,707.
Application 08/428734 is a continuation in part of application No. 08/316305, filed on Sep. 30, 1994, abandoned.
Application 08/316305 is a continuation in part of application No. 08/235398, filed on Apr. 28, 1994, abandoned.
Application 08/235398 is a continuation in part of application No. 08/112608, filed on Aug. 26, 1993, abandoned.
Application 08/112608 is a continuation in part of application No. 07/965662, filed on Oct. 23, 1992, abandoned.
Claims priority of application No. PCT/US93/10168 (WO), filed on Oct. 22, 1993.
Prior Publication US 2003/0018181 A1, Jan. 23, 2003
Int. Cl. A61K 38/00 (2006.01); A61K 39/395 (2006.01)
U.S. Cl. 514—2  [424/178.1; 424/185.1; 424/195.11; 514/7; 514/8; 514/12] 16 Claims
 
1. A method of reducing leukocyte adhesion to endothelial cells in a subject having an inflammatory disease comprising administering to the subject a therapeutically effective amount of a composition comprising a fusion protein comprising:
(a) amino acid sequence comprising amino acid 42 to amino acid 60 of SEQ ID NO:2, and
(b) the Fc portion of an antibody.